Solstice Raises $21 Million in Series A Funding

Solstice, an AI-native marketing platform focused on the pharmaceutical and life sciences sectors, has announced a successful Series A funding round totaling $21 million. The round, which closed on May 28, 2026, was led by Transformation Capital with participation from Twelve Below and Virtue Ventures.

Accelerating Pharma Campaigns

Founded by Aris Saxena and Yiwen Li, Solstice aims to significantly reduce the time required for launching compliant marketing campaigns in the pharma industry. By leveraging AI technology, Solstice enables its clients to cut campaign timelines from three months to just ten days, providing a more efficient path for pharmaceutical companies to reach their target audiences.

Leadership and Vision

Aris Saxena, Co-Founder of Solstice, expressed confidence in the company's direction, stating: "This funding will allow us to expand our capabilities and further our mission to streamline marketing processes in the pharmaceutical sector." Co-Founder Yiwen Li added that the investment will help the company to "scale operations and enhance their AI-driven solutions".

Use of Funds

The newly acquired funds are earmarked for several strategic initiatives. Solstice plans to enhance its AI platform to offer more robust and compliant solutions for its clients. Additionally, the company intends to expand its team, focusing on hiring experts in AI and pharma marketing to support its growth ambitions.

Investors and Market Impact

The investment from Transformation Capital, a firm known for backing innovative health tech companies, underscores the growing interest in AI applications within the pharmaceutical industry. The participation of Twelve Below and Virtue Ventures also highlights the broad support for Solstice's approach to transforming pharma marketing.

Location and Operations

Headquartered in New York City, Solstice is strategically positioned to leverage the city's robust tech and pharmaceutical ecosystems. This location provides the company with access to a wealth of resources and potential partnerships that are critical for its expansion plans.

With this significant infusion of capital, Solstice is well-positioned to drive innovation in pharma marketing, offering its clients faster, more efficient, and compliant campaign solutions.